The marginal zone lymphoma market reached a value of USD 1.8 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 3.0 Billion by 2035, exhibiting a growth rate (CAGR) of 4.74% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 1.8 Billion |
Market Forecast in 2035
|
USD 3.0 Billion |
Market Growth Rate 2025-2035
|
4.74% |
The marginal zone lymphoma market has been comprehensively analyzed in IMARC's new report titled "Marginal Zone Lymphoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Marginal zone lymphoma is a type of non-Hodgkin lymphoma that arises from the marginal zone B cells in the lymphoid tissue. Some of the common symptoms include painless swelling of lymph nodes, particularly in the neck, armpits, or groin, as well as various nonspecific indications, like fatigue, night sweats, unexplained weight loss, fever, etc. In a few cases, the ailment may affect extranodal sites, leading to symptoms specific to the impacted organ, such as abdominal pain, gastrointestinal bleeding, respiratory difficulties, etc. The diagnosis of marginal zone lymphoma involves a combination of clinical evaluation, imaging studies, laboratory investigations, and histopathological examination. Several diagnostic imaging tests, including computed tomography (CT) scan and positron emission tomography (PET) scan, help in evaluating the extent of disease progression and identifying affected lymph nodes as well as extranodal sites. A definitive diagnosis is made through a lymph node or tissue biopsy, followed by a histopathological examination by a pathologist, which consists of microscopic analysis, immunohistochemistry, and flow cytometry to determine the presence of lymphoma cells and classify the specific subtype of the ailment.
The rising cases of specific genetic and molecular alterations that can disrupt normal cellular processes and interfere with the regulation of signaling pathways involved in cell survival and immune responses are primarily driving the marginal zone lymphoma market. In addition to this, the escalating utilization of localized radiation therapy, which involves directing high-energy beams to the affected lymph nodes or organs, for controlling the disease and providing long-term remission, is creating a positive outlook for the market. Moreover, the increasing adoption of stem cell transplantation for replacing diseased bone marrow with stem cells to allow the production of new, healthy blood cells is also bolstering the market growth. Additionally, the rising demand for antibody-drug conjugates for treating the ailment on account of their several associated benefits, including enhanced efficacy, targeted therapy, reduced systemic toxicity, etc., is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of cytogenetic analysis, such as chromosomal microarray analysis (CMA), since it aids in detecting chromosomal aberrations, including translocations or deletions, that can help in providing prognostic information and differentiating the ailment from other lymphoma subtypes, is expected to drive the marginal zone lymphoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the marginal zone lymphoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for marginal zone lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the marginal zone lymphoma market in any manner.
Brukinsa (zanubrutinib) treats marginal zone lymphoma by inhibiting Bruton's tyrosine kinase (BTK), a protein crucial for the growth and survival of malignant B-cells. It works by forming a covalent bond with a specific cysteine residue in the BTK enzyme's active site, effectively blocking its activity. This disruption of BTK signaling pathways prevents the proliferation, trafficking, and survival of malignant B-cells, ultimately leading to tumor shrinkage.
Loncastuximab tesirine is a CD19-specific antibody-drug conjugate (ADC). After binding to a CD19-expressing cell, loncastuximab tesirine is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to the DNA minor groove with minimal distortion, making it less detectable to DNA repair machinery. This finally leads to cell cycle arrest and tumor cell death.
Tafasitamab is a CD19-directed cytolytic monoclonal antibody used in the treatment of marginal zone lymphoma. Its mechanism of action involves binding to CD19, a protein found on most B cells and some lymphoma cells, leading to the destruction of cancer cells through various immune-mediated mechanisms.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current marginal zone lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Brukinsa (Zanubrutinib) | BeiGene |
Revlimid (Lenalidomide) | Bristol-Myers Squibb |
Loncastuximab tesirine | ADC Therapeutics |
Tafasitamab | Incyte Corporation |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Marginal Zone Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies